Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
To compare the effects of exemestane for 5 years versus tamoxifen and exemestane given
sequentially over 5 years in the adjuvant treatment of postmenopausal women with early breast
cancer.
This Pfizer sponsored trial is part of an international collaboration of investigators
conducting 7 similar yet independent studies in 9 countries. This study is designed to be
part of the larger TEAM trial where the data from these 7 studies will be combined. A
pre-specified analysis of the pooled data will be conducted.